RARE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ultragenyx Pharmaceutical Inc (RARE) is not a strong buy at this moment for a beginner investor with a long-term horizon. The stock is currently trading in a neutral zone with no clear technical or proprietary trading signals. While analysts have mixed views, the company's financial performance shows declining profitability, and there are no significant recent positive catalysts to justify immediate action.
The MACD is positive but contracting, RSI is neutral at 67.279, and moving averages are converging, indicating no strong trend. The stock is trading near its pivot level of 23.551 with resistance at 25.614 and support at 21.488.
Morgan Stanley sees a favorable asymmetric setup for GTX-102 Phase 3 data in 2026, with potential upside of 50%-70%. The company is focused on cost reductions, which could pave the way for profitability in 2027.
Goldman Sachs downgraded the stock to Neutral, citing risks in the GTX-102 trial design and heterogeneity. The stock has seen multiple price target reductions due to disappointing clinical trial results and uneven revenue patterns.
In Q4 2025, revenue increased by 25.72% YoY to $207.28M, but net income dropped by 3.62% YoY to -$128.56M. EPS declined by 7.19% YoY to -1.29, and gross margin decreased by 4.36% YoY to 85.84%.
Analysts have mixed ratings. Morgan Stanley and JPMorgan maintain positive outlooks with high price targets, while Goldman Sachs and others have downgraded the stock or reduced price targets due to clinical trial risks and uneven revenue patterns.
